Evaluation of clinical implementation of prospective

Fluoropyrimidines are commonly used anti-cancer drugs, but lead to severe toxicity in 10-30% of patients. Prospective screening identifies patients at risk for toxicity and leads to a safer treatment with fluoropyrimidines. This study evaluated the routinely application of prospective screening at t...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2016-05, Vol.17 (7), p.721-729
Main Authors: Lunenburg, Carin ATC, van Staveren, Maurice C, Gelderblom, Hans, Guchelaar, Henk-Jan, Swen, Jesse J
Format: Article
Language:English
Subjects:
5-fluorouracil
capecitabine
dihydropyrimidine dehydrogenase
dose reductions
fluoropyrimidines
implementation
screening
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 729
container_issue 7
container_start_page 721
container_title Pharmacogenomics
container_volume 17
creator Lunenburg, Carin ATC
van Staveren, Maurice C
Gelderblom, Hans
Guchelaar, Henk-Jan
Swen, Jesse J
description Fluoropyrimidines are commonly used anti-cancer drugs, but lead to severe toxicity in 10-30% of patients. Prospective screening identifies patients at risk for toxicity and leads to a safer treatment with fluoropyrimidines. This study evaluated the routinely application of prospective screening at the Leiden University Medical Center. Prospective screening as part of routine patient care was evaluated by retrospectively screening databases and patient files to determine genotype, treatment, dose recommendations and dose adjustments. 86.9% of all patients with a first fluoropyrimidine prescription were screened. Fourteen out of 275 patients (5.1%) carried a variant and received a 25-50% dose reduction recommendation. None of the patients with a variant treated with a reduced dose developed toxicities. Prospective screening can be implemented successfully in a real world clinical setting, is well accepted by physicians and results in low toxicity.
doi_str_mv 10.2217/pgs-2016-0013
format article
fullrecord <record><control><sourceid>futurescience</sourceid><recordid>TN_cdi_futurescience_futuremedicine_10_2217_pgs_2016_0013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_pgs_2016_0013</sourcerecordid><originalsourceid>FETCH-futurescience_futuremedicine_10_2217_pgs_2016_00133</originalsourceid><addsrcrecordid>eNqlzk0KwjAQBeAgCv4u3fcC0Zk0pLqWigdwH0qcSiRNQ5P2_LYoXsDVvOHx4GNsj3AQAotjeEYuABUHwHzGVlhIyU8gxXzMUgkuJKolW8f4AhCoJKyYLIfK9VWyrc_aOjPOemsql9kmOGrIp18VujYGMskOtGWLunKRdt-7Yedreb_ceN2nvqNoLHlD-vM19LDGetIIemLqkaknpp6Y-T_bNzgLSx8</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of clinical implementation of prospective</title><source>PubMed Central(OpenAccess)</source><creator>Lunenburg, Carin ATC ; van Staveren, Maurice C ; Gelderblom, Hans ; Guchelaar, Henk-Jan ; Swen, Jesse J</creator><creatorcontrib>Lunenburg, Carin ATC ; van Staveren, Maurice C ; Gelderblom, Hans ; Guchelaar, Henk-Jan ; Swen, Jesse J</creatorcontrib><description>Fluoropyrimidines are commonly used anti-cancer drugs, but lead to severe toxicity in 10-30% of patients. Prospective screening identifies patients at risk for toxicity and leads to a safer treatment with fluoropyrimidines. This study evaluated the routinely application of prospective screening at the Leiden University Medical Center. Prospective screening as part of routine patient care was evaluated by retrospectively screening databases and patient files to determine genotype, treatment, dose recommendations and dose adjustments. 86.9% of all patients with a first fluoropyrimidine prescription were screened. Fourteen out of 275 patients (5.1%) carried a variant and received a 25-50% dose reduction recommendation. None of the patients with a variant treated with a reduced dose developed toxicities. Prospective screening can be implemented successfully in a real world clinical setting, is well accepted by physicians and results in low toxicity.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2016-0013</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>5-fluorouracil ; capecitabine ; dihydropyrimidine dehydrogenase ; dose reductions ; fluoropyrimidines ; implementation ; screening</subject><ispartof>Pharmacogenomics, 2016-05, Vol.17 (7), p.721-729</ispartof><rights>Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Lunenburg, Carin ATC</creatorcontrib><creatorcontrib>van Staveren, Maurice C</creatorcontrib><creatorcontrib>Gelderblom, Hans</creatorcontrib><creatorcontrib>Guchelaar, Henk-Jan</creatorcontrib><creatorcontrib>Swen, Jesse J</creatorcontrib><title>Evaluation of clinical implementation of prospective</title><title>Pharmacogenomics</title><description>Fluoropyrimidines are commonly used anti-cancer drugs, but lead to severe toxicity in 10-30% of patients. Prospective screening identifies patients at risk for toxicity and leads to a safer treatment with fluoropyrimidines. This study evaluated the routinely application of prospective screening at the Leiden University Medical Center. Prospective screening as part of routine patient care was evaluated by retrospectively screening databases and patient files to determine genotype, treatment, dose recommendations and dose adjustments. 86.9% of all patients with a first fluoropyrimidine prescription were screened. Fourteen out of 275 patients (5.1%) carried a variant and received a 25-50% dose reduction recommendation. None of the patients with a variant treated with a reduced dose developed toxicities. Prospective screening can be implemented successfully in a real world clinical setting, is well accepted by physicians and results in low toxicity.</description><subject>5-fluorouracil</subject><subject>capecitabine</subject><subject>dihydropyrimidine dehydrogenase</subject><subject>dose reductions</subject><subject>fluoropyrimidines</subject><subject>implementation</subject><subject>screening</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqlzk0KwjAQBeAgCv4u3fcC0Zk0pLqWigdwH0qcSiRNQ5P2_LYoXsDVvOHx4GNsj3AQAotjeEYuABUHwHzGVlhIyU8gxXzMUgkuJKolW8f4AhCoJKyYLIfK9VWyrc_aOjPOemsql9kmOGrIp18VujYGMskOtGWLunKRdt-7Yedreb_ceN2nvqNoLHlD-vM19LDGetIIemLqkaknpp6Y-T_bNzgLSx8</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Lunenburg, Carin ATC</creator><creator>van Staveren, Maurice C</creator><creator>Gelderblom, Hans</creator><creator>Guchelaar, Henk-Jan</creator><creator>Swen, Jesse J</creator><general>Future Medicine Ltd</general><scope/></search><sort><creationdate>20160501</creationdate><title>Evaluation of clinical implementation of prospective</title><author>Lunenburg, Carin ATC ; van Staveren, Maurice C ; Gelderblom, Hans ; Guchelaar, Henk-Jan ; Swen, Jesse J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-futurescience_futuremedicine_10_2217_pgs_2016_00133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>5-fluorouracil</topic><topic>capecitabine</topic><topic>dihydropyrimidine dehydrogenase</topic><topic>dose reductions</topic><topic>fluoropyrimidines</topic><topic>implementation</topic><topic>screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lunenburg, Carin ATC</creatorcontrib><creatorcontrib>van Staveren, Maurice C</creatorcontrib><creatorcontrib>Gelderblom, Hans</creatorcontrib><creatorcontrib>Guchelaar, Henk-Jan</creatorcontrib><creatorcontrib>Swen, Jesse J</creatorcontrib><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lunenburg, Carin ATC</au><au>van Staveren, Maurice C</au><au>Gelderblom, Hans</au><au>Guchelaar, Henk-Jan</au><au>Swen, Jesse J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of clinical implementation of prospective</atitle><jtitle>Pharmacogenomics</jtitle><date>2016-05-01</date><risdate>2016</risdate><volume>17</volume><issue>7</issue><spage>721</spage><epage>729</epage><pages>721-729</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>Fluoropyrimidines are commonly used anti-cancer drugs, but lead to severe toxicity in 10-30% of patients. Prospective screening identifies patients at risk for toxicity and leads to a safer treatment with fluoropyrimidines. This study evaluated the routinely application of prospective screening at the Leiden University Medical Center. Prospective screening as part of routine patient care was evaluated by retrospectively screening databases and patient files to determine genotype, treatment, dose recommendations and dose adjustments. 86.9% of all patients with a first fluoropyrimidine prescription were screened. Fourteen out of 275 patients (5.1%) carried a variant and received a 25-50% dose reduction recommendation. None of the patients with a variant treated with a reduced dose developed toxicities. Prospective screening can be implemented successfully in a real world clinical setting, is well accepted by physicians and results in low toxicity.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/pgs-2016-0013</doi></addata></record>
fulltext fulltext
identifier ISSN: 1462-2416
ispartof Pharmacogenomics, 2016-05, Vol.17 (7), p.721-729
issn 1462-2416
1744-8042
language eng
recordid cdi_futurescience_futuremedicine_10_2217_pgs_2016_0013
source PubMed Central(OpenAccess)
subjects 5-fluorouracil
capecitabine
dihydropyrimidine dehydrogenase
dose reductions
fluoropyrimidines
implementation
screening
title Evaluation of clinical implementation of prospective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A11%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20clinical%20implementation%20of%20prospective&rft.jtitle=Pharmacogenomics&rft.au=Lunenburg,%20Carin%20ATC&rft.date=2016-05-01&rft.volume=17&rft.issue=7&rft.spage=721&rft.epage=729&rft.pages=721-729&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2016-0013&rft_dat=%3Cfuturescience%3E10_2217_pgs_2016_0013%3C/futurescience%3E%3Cgrp_id%3Ecdi_FETCH-futurescience_futuremedicine_10_2217_pgs_2016_00133%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true